Clinical data | |
---|---|
Trade names | Glucotrol, Glucotrol XL, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a684060 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Sulfonylurea |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 100% (regular formulation) 90% (extended release) |
Protein binding | 98 to 99% |
Metabolism | Liver hydroxylation |
Elimination half-life | 2 to 5 hours |
Excretion | Kidney and fecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.044.919 |
Chemical and physical data | |
Formula | C21H27N5O4S |
Molar mass | 445.54 g·mol−1 |
3D model (JSmol) | |
Melting point | 208 to 209 °C (406 to 408 °F) |
| |
| |
(what is this?) (verify) |
Glipizide, sold under the brand name Glucotrol among others, is an anti-diabetic medication of the sulfonylurea class used to treat type 2 diabetes.[1][2] It is used together with a diabetic diet and exercise.[1][2] It is not indicated for use by itself in type 1 diabetes.[1][2] It is taken by mouth.[1][2] Effects generally begin within half an hour and can last for up to a day.[1]
Common side effects include nausea, diarrhea, low blood sugar, and headache.[1] Other side effects include sleepiness, skin rash, and shakiness.[3] The dose may need to be adjusted in those with liver or kidney disease.[1] Use during pregnancy or breastfeeding is not recommended.[3] It works by stimulating the pancreas to release insulin and increases tissue sensitivity to insulin.[1]
Glipizide was approved for medical use in the United States in 1984.[1] It is available as a generic medication.[1] In 2022, it was the 42nd most commonly prescribed medication in the United States, with more than 14 million prescriptions.[4][5]
Glucotrol FDA label
was invoked but never defined (see the help page).